ACR Meeting Abstracts

ACR Meeting Abstracts

  • Meetings
    • ACR Convergence 2024
    • ACR Convergence 2023
    • 2023 ACR/ARP PRSYM
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • ACR Meetings

Abstract Number: 2922

Disability, Fatigue, and Their Associates in Early Diffuse Cutaneous Systemic Sclerosis

Ariane L. Herrick1, Sébastien Peytrignet2, Xiaoyan Pan3, Roger Hesselstrand4, Luc Mouthon5, László Czirják6, Madelon C. Vonk7, Oliver Distler8, Joerg H.W Distler9, Edith Brown3, Kim Fligelstone3, Rachel Ochiel10, William Gregory11, Alan Silman12, Mark Lunt13 and Christopher Denton14, 1Centre for Musculoskeletal Research, University of Manchester, MAHSC, Salford Royal Hospital, Manchester, United Kingdom, 2Manchester Academic Health Sciences Centre, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 3Manchester Academic Health Science Centre, Centre for Musculoskeletal Research, Institute of Inflammation and Repair, The University of Manchester, Manchester, United Kingdom, 4Department of Rheumatology, Lund University, Lund, Sweden, 5Internal Medicine, Hopital Cochin, Paris, France, 6Department of Rheumatology and Immunology, University of Pécs, Faculty of Medicine, Pécs, Hungary, 7Department of the Rheumatic Diseases, Radboud University Nijmegen Medical Centre, Nijmegen, Netherlands, 8Department of Rheumatology, University Hospital Zurich, Zurich, Switzerland, 9Department of Internal Medicine 3, Rheumatology and Immunology, Friedrich-Alexander University Erlangen-Nuremberg, Erlangen, Germany, 10Royal Free London NHS Foundation Trust, London, United Kingdom, 11Rehabilitation Services, Salford Royal NHS Foundation Trust, Salford, United Kingdom, 12Nuffield Department of Orthopaedics, Rheumatology and Musculoskeletal Sciences, University of Oxford, Oxford, United Kingdom, 13Arthritis Research UK Epidemiology Unit, The University of Manchester, Manchester Academic Health Sciences Centre, Manchester, United Kingdom, 14Centre for Rheumatology, Royal Free Hospital, London, Great Britain

Meeting: 2016 ACR/ARHP Annual Meeting

Date of first publication: September 28, 2016

Keywords: Disability, Fatigue, Hand function, systemic sclerosis and ulcers

  • Tweet
  • Email
  • Print
Session Information

Date: Tuesday, November 15, 2016

Title: Systemic Sclerosis, Fibrosing Syndromes, and Raynaud's – Clinical Aspects and Therapeutics - Poster III

Session Type: ACR Poster Session C

Session Time: 9:00AM-11:00AM

Background/Purpose: ESOS (European Scleroderma Observational Study) was a prospective observational study of 326 patients with early diffuse cutaneous systemic sclerosis (dcSSc) from 50 centres. Here we describe the burden of disease in terms of disability and fatigue in this very early disease cohort (median disease duration 11.9 months), and explore disease features that associate with this burden.

Methods: Patients completed questionnaires at study entry and at 12 months: the Scleroderma Specific Health Assessment Questionnaire (sHAQ, including HAQ-DI disability index), Functional Assessment of Chronic Illness Therapy [FACIT]-fatigue, the Short Form 36 [SF36] and the Cochin Hand Function Scale (CHFS). Covariates examined included the modified Rodnan skin score (mRSS) and other parameters listed in Table 1. The distribution of the HAQ-DI, fatigue and hand function scores was compared between levels of categorical variables using Kruskal-Wallis’ test and correlations with other continuous variables were assessed using Spearman’s coefficient (ρ). For continuous variables, correlations between 12-month changes were also computed.

Results: Baseline scores of HAQ-DI, FACIT and CHFS, and associates are shown in Table 1. High levels of skin fibrosis (mRSS) were associated with poor hand function (ρ=0.35) and high HAQ-DI scores (ρ=0.34). The median CHFS (0-90 scale) and HAQ-DI (0-3 scale) scores were higher by 8.5 and 0.6 units (indicating poorer hand function and increased disability) in patients with current digital ulcers. The median HAQ-DI score was higher by one unit in patients with muscle involvement, and was also higher in patients with lung fibrosis and heart involvement. Cardiac, pulmonary and renal involvement were each associated with higher levels of fatigue. Patients currently or previously on corticosteroids had more disability and fatigue than patients who had never been prescribed these. As anticipated, HAQ-DI, FACIT, CHFS and SF36 scores were all highly correlated. The 12-month change in HAQ-DI had a strong association with the change in hand function (ρ=0.56), and increasing levels of skin fibrosis were correlated with increasing HAQ-DI scores (ρ=0.40).

Conclusion:

1.    ESOS benchmarks the burden of disability in early dcSSc, with high levels of disability and fatigue, and will provide comparative data for future clinical trials.

2.    The degree of disability/fatigue is associated with severity of skin thickening (mRSS), with changes in HAQ-DI over 12 months correlating with changes in mRSS.

3.    Impaired hand function is a major contributor to overall disability.

4.    Disability and fatigue associate with internal organ involvement, and overall (HAQ-DI) and hand disability with digital ulcers. Table 1. Baseline associates of disability, median and interquartile range (for levels within binary variables) and correlations (for pairs of continuous variables).


Disclosure: A. L. Herrick, None; S. Peytrignet, None; X. Pan, None; R. Hesselstrand, None; L. Mouthon, None; L. Czirják, None; M. C. Vonk, None; O. Distler, 4D Science, 5,Actelion Pharmaceuticals US, 5,Active Biotech, 5,Bayer, 5,Biogenidec, 5,BMS, 5,Boehringer Ingelheim, 5,EpiPharm, 5,Ergonex, 5,espeRare Foundation, 5,Genentech/Roche, 5,GSK, 5,Inventiva, 5,Lilly, 5,Medac, 5,Medimmune, 5,Pharmacyclics, 5,Pfizer Inc, 5,Serodapharm, 5,Sinoxa, 5,Actelion Pharmaceuticals US, 2,Bayer, 2,Boehringer Ingelheim, 2,Ergonex, 2,Pfizer Inc, 2,Sanofi-Aventis Pharmaceutical, 2; J. H. W. Distler, Actelion Pharmaceuticals US, 5,BMS, 5,Celgene, 5,Bayer Pharma, 5,Boehringer Ingelheim, 5,JB Therapeutics, 5,Sanofi-Aventis, 5,Novartis Pharmaceutical Corporation, 5,UCB, 5,GSK, 5,Array Biopharma, 5,Active Biotech, 5,Galapagos, 5,Inventiva, 5,Medac, 5,Pfizer Inc, 5,Anamar Medical, 5,RuiYi, 5,4D Science GmbH, 1; E. Brown, None; K. Fligelstone, None; R. Ochiel, None; W. Gregory, Pfizer Inc, 9; A. Silman, None; M. Lunt, None; C. Denton, GSK, 5,Actelion Pharmaceuticals US, 5,Bayer, 5,Inventiva, 5,Merck-Serono, 5,GSK, 2,Actelion, 2,CSL Behring, 2,Inventiva, 2,Bayer, 9,Merck-Serono, 9.

To cite this abstract in AMA style:

Herrick AL, Peytrignet S, Pan X, Hesselstrand R, Mouthon L, Czirják L, Vonk MC, Distler O, Distler JHW, Brown E, Fligelstone K, Ochiel R, Gregory W, Silman A, Lunt M, Denton C. Disability, Fatigue, and Their Associates in Early Diffuse Cutaneous Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2016; 68 (suppl 10). https://acrabstracts.org/abstract/disability-fatigue-and-their-associates-in-early-diffuse-cutaneous-systemic-sclerosis/. Accessed .
  • Tweet
  • Email
  • Print

« Back to 2016 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/disability-fatigue-and-their-associates-in-early-diffuse-cutaneous-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

Wiley

  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences

© Copyright 2025 American College of Rheumatology